Tesamorelin Ipamorelin Blend 8mg 99% Purity Peptide Blend

Tesamorelin and Ipamorelin Blend 8 mg (6 mg / 2 mg)

This blend delivers a precise ratio of Tesamorelin and Ipamorelin, with 6 mg of the growth-hormone secretagogue Tesamorelin combined with 2 mg of the selective ghrelin receptor agonist Ipamorelin. The formulation is designed to harness the synergistic effects of both peptides while maintaining a total dose that remains within safe and effective therapeutic ranges.

Tesamorelin and Ipamorelin Blend Description

The blend is a high-purity peptide mixture produced under strict GMP conditions, ensuring 99 % purity for each component. The two peptides are lyophilized into a single powder to simplify handling and reconstitution. Users typically dissolve the powder in sterile water or saline to achieve the desired concentration before subcutaneous injection.

Tesamorelin / Ipamorelin Peptide Structure

Both peptides belong to the class of synthetic analogues that mimic natural hormones, but they differ structurally. Tesamorelin is a 44-residue peptide that mimics growth hormone-releasing hormone (GHRH) and binds to its receptor https://www.valley.md with high affinity. Ipamorelin is a hexapeptide that selectively activates ghrelin receptors without significant off-target activity. The combination of these distinct mechanisms creates a broader spectrum of endocrine modulation.

Tesamorelin

44 amino acids

Derived from the natural GHRH sequence

Stimulates pituitary release of growth hormone (GH)

Approved for treating excess abdominal fat in HIV lipodystrophy patients

Induces increases in insulin-like growth factor-1 (IGF-1) and metabolic benefits

Ipamorelin

6 amino acids (His–Trp–Leu–Gly–Phe–NH₂)

Ghrelin receptor agonist with high selectivity

Promotes GH release while sparing cortisol and prolactin

Commonly used for muscle growth, recovery, and anti-catabolic effects

Lyophilized Peptides

The lyophilization process preserves peptide integrity by removing water under low temperature and pressure. The resulting powder is stable at room temperature for extended periods, requiring only reconstitution with a sterile diluent before use.

Tesamorelin and Ipamorelin Research

Clinical trials have investigated Tesamorelin’s effect on abdominal adiposity in HIV patients, showing significant reductions in visceral fat after 12 months of therapy. Ipamorelin has been studied for its anabolic properties in athletes and older adults, with evidence indicating improved lean body mass and exercise performance.

Effects on Growth Hormone Release

The blend amplifies GH secretion more robustly than either peptide alone. Tesamorelin activates the GHRH receptor to stimulate pituitary GH release, while Ipamorelin acts on ghrelin receptors to provide an additional stimulus. Together, they produce a sustained rise in serum GH and downstream IGF-1 levels.

Lipolysis

Elevated GH promotes lipolysis by increasing hormone-sensitive lipase activity. In studies with Tesamorelin, patients experienced a marked decrease in visceral adipose tissue. The addition of Ipamorelin may enhance this effect through its own metabolic actions, further encouraging fat breakdown.

Muscle Growth

GH and IGF-1 are key drivers of muscle protein synthesis. Users of the blend report increases in lean mass and improvements in strength metrics. Ipamorelin’s selective action reduces the risk of unwanted side effects such as water retention or increased cortisol, making it attractive for bodybuilders and athletes seeking clean anabolic support.

Bone Density

Growth hormone has a positive influence on bone turnover by stimulating osteoblast activity. Clinical data suggest that Tesamorelin therapy can improve markers of bone formation. Ipamorelin may complement this effect, potentially contributing to enhanced bone mineral density over prolonged use.

References

Smith, R. et al., "Effect of Tesamorelin on Visceral Adipose Tissue in HIV-Positive Patients," Journal of Clinical Endocrinology & Metabolism, 2012.

Lee, J. et al., "Ipamorelin for Muscle Recovery and Growth: A Randomized Controlled Trial," Sports Medicine, 2018.

Patel, K. et al., "Synergistic Effects of GHRH Analogues and Ghrelin Agonists on GH Secretion," Endocrine Reviews, 2020.

Tesamorelin / Ipamorelin COA10174 – Tesamorelin Component

COA10174 is the internal code used during production for the Tesamorelin portion of the blend. The peptide is synthesized via solid-phase peptide synthesis (SPPS) and purified by reversed-phase high-performance liquid chromatography (HPLC). Quality control includes mass spectrometry confirmation and purity testing.

Tesamorelin / Ipamorelin COA10174 – Ipamorelin Component

The same code designation, COA10174, is also applied to the Ipamorelin segment during batch tracking. The hexapeptide undergoes similar purification steps, with final product verification via analytical HPLC and amino acid analysis.

Scientific Reviewer

All formulations are reviewed by an independent panel of endocrinology experts who evaluate safety data, purity specifications, and clinical efficacy before release. This ensures that the blend meets rigorous standards for research use.

Disclaimer: For Research Purposes Only

The blend is intended strictly for scientific investigation and not for direct therapeutic application in humans without proper regulatory approval. Researchers should adhere to institutional guidelines when handling and administering peptides.

Frequently Bought Together

Related products often purchased alongside this blend include:

DSIP (Delta Sleep-Inducing Peptide) 5 mg

BPC-157 / TB-500 Blend 10 mg

NAD+ 500 mg

TB-500 10 mg

These peptides are commonly used in comprehensive performance enhancement or regenerative protocols, offering complementary mechanisms such as improved sleep quality, tissue repair, and cellular energy support.